Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2015

View Archived Issues

Principia evaluating PRN-1371 in phase I trial for advanced solid tumors

Effector Therapeutics initiates trial of Mnk1/2 inhibitor eFT-508 in patients with solid tumors

FXR agonist EYP-001 shows activity against HBV replication

EMA accepts Helsinn's MAA for anamorelin in cancer-related cachexia

New CD137/HER2 bispecific Anticalin-based protein shows promising antitumoral activity

Fibroblast activation inhibitor preserves cardiac function after heart failure in animal model

Sprint Bioscience collaborates with Gothenburg University on diabetes program

University of Colorado patents HDAC/TTK inhibitors

Takeda and Teva to form Japanese generic pharmaceuticals venture

Peloton Therapeutics disclosed ACSS2 inhibitors

AbbVie announces V1bR ligands

X-Rx reports autotaxin inhibitors

Array BioPharma patents Trk-A inhibitor

Bayer Schering Pharma divulges sGC activators

Novartis discloses TLR7 agonists

FDA issues complete response letter for Opdivo

EC grants marketing authorization for Numient in the treatment of Parkinson's disease

Oncoceutics starts phase I trial of ONC-201 in solid tumors and multiple myeloma

Rottapharm's antibody CRB-0017 prevents joint damage in animal models of osteoarthritis

PCSK9 vaccine reduces cholesterol and triglyceride levels in mice and monkeys

Gene therapy that restores copper metabolism in model of Wilson disease granted E.U. orphan status

Novel biomarkers of lupus nephritis activity identified through urinary proteomics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...